Get the latest tech news
Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan
Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT reports.
Altman previously provided Retro Biosciences’ entire seed round of $180 million. CEO Joe Betts-LaCroix told the FT he wants to move fast by discovering and developing a drug “in the 2020s.” The startup joins other major billionaire-backed longevity efforts, including Altos Labs, which launched with $3 billion in 2022 backed by Jeff Bezos, and Unity Biotechnology, supported by both Bezos and Peter Thiel.
Or read this on TechCrunch
